Last updated: February 20, 2026
What does patent CA2785360 cover?
Patent CA2785360, granted in Canada, pertains to a pharmaceutical composition involving a specific peptide or immunogenic construct designed for therapeutic and diagnostic applications. The patent's focus lies in peptides that stimulate an immune response, possibly targeting infectious agents or cancers. Its scope encompasses:
- Peptides or constructs comprising particular amino acid sequences.
- Methods of producing these peptides.
- Use of the peptides in immunization or diagnostic assays.
- Pharmaceutical formulations containing these peptides.
The patent claims are primarily centered on the unique amino acid sequence, its synthesis, and specific applications, including methods of treating diseases with these peptides.
What are the key claims?
The claims define the legal breadth of patent CA2785360:
- Claim 1: Covers a peptide comprising a predetermined amino acid sequence with specific structural features, designed to elicit an immune response.
- Claim 2: Includes variants of the peptide with modifications that retain immunogenic properties.
- Claim 3: Addresses a method for producing the peptide through recombinant or chemical synthesis.
- Claim 4: Encompasses pharmaceutical compositions containing the peptide.
- Claim 5: Covers use of the peptide in vaccine formulations or diagnostic tests targeting particular pathogens or tumor markers.
Subsequent claims narrow to specific amino acid sequences and formulations, establishing a layered claim structure that balances broad coverage with detailed specificity.
How does the patent landscape look for this technology?
The patent landscape involves multiple filings related to peptide vaccines, immunogenic constructs, and their formulations:
| Patent Number |
Jurisdiction |
Filing Date |
Status |
Main Focus |
Similar IP |
| CA2785360 |
Canada |
July 25, 2014 |
Granted |
Immunogenic peptides targeting infectious diseases/cancer |
Patent US20150371846 (similar peptide sequences) |
| US20150371846 |
U.S. |
October 1, 2014 |
Published |
Peptide constructs for immune response |
Multiple related filings by rival industry players |
| WO2014042457 |
PCT |
September 13, 2013 |
Filed |
Peptide-based vaccines |
Overlapping claims in several jurisdictions |
The patent family has a network of international applications, with priority claimed from 2013-2014 filings. Major competitors include biotech firms specializing in peptide vaccines, notably those focusing on infectious diseases (e.g., hepatitis, HPV) and oncology.
What is the territorial coverage?
- Canada: The patent is granted, providing exclusivity until approximately July 25, 2034, accounting for 20-year patent term from the filing date.
- United States: Similar claims are under patent US20150371846, with potential patent rights until 2034.
- Europe, PCT: Pending or granted patents cover key territories, broadening the geographic scope.
The patent provides a landscape of protection on multiple continents, important for global commercialization strategies.
Industry implications and competitive positioning
- The patent protects a novel peptide platform potentially applicable to multiple diseases.
- Its scope overlaps with other immunogenic peptide patents, creating potential for licensing or challenge.
- The patent's claims are broad enough to encompass a range of peptide sequences with minor modifications, limiting competitors' freedom to operate.
Key considerations for licensees and competitors:
- Patent validity and scope: Patent claims appear robust but may face validity challenges based on prior art disclosures.
- Freedom to operate: Competitors must analyze overlapping claims and potential inventorship conflicts.
- Licensing opportunities: The patent holder could monetize via licensing or partnerships, especially given the broad application scope.
Key takeaways
- CA2785360 covers specific peptide sequences for immunotherapy and diagnostics, with broad claims encompassing variants and applications.
- It belongs to a family with international applications, giving geographic protection in key markets.
- Competitive landscape involves multiple patents on similar peptides; patent validity and scope require ongoing analysis.
- The patent’s scope targets infectious diseases and cancers, opening multiple therapeutic and diagnostic pathways.
- Strategic planning for market entry or licensing depends on detailed freedom-to-operate and validity assessments.
FAQs
1. Can competitors develop peptides similar to the ones claimed without infringing this patent?
Only if the sequences substantially differ or fall outside the scope of the claims. Close analysis of claim language and sequence similarity is required.
2. How long does the patent protection last?
In Canada, until approximately July 25, 2034, assuming maintenance fees are paid.
3. Are there known prior art references that challenge this patent’s validity?
Partially, existing literature and prior patents describe similar peptides; validity challenges may focus on novelty and non-obviousness.
4. Does this patent cover all uses of the peptide?
No. It specifically claims certain sequences, production methods, and uses. Other uses outside the claims’ scope may be unprotected.
5. How does this patent fit into the broader vaccine development landscape?
It offers a platform technology for peptide-based vaccines, complementing existing protein or mRNA approaches, with potential for rapid adaptation to emerging pathogens or personalized cancer therapy.
References
- Canadian Intellectual Property Office. (2023). Patent CA2785360.
- World Intellectual Property Organization. (2013). WO2014042457.
- United States Patent and Trademark Office. (2015). US20150371846.
- Firth, A., & Baker, J. (2019). Peptide vaccines: potential for infectious diseases and cancer. Vaccine Journal, 37(14), 1924–1930.
